Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Item
http://www.wikidata.org/entity/Q45402744
Clinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationSimulated estimates of pre-pregnancy and gestational diabetes mellitus in the US: 1980 to 2008.Cost-utility analysis of glucagon-like Peptide-1 agonists compared with dipeptidyl peptidase-4 inhibitors or neutral protamine hagedorn Basal insulin as add-on to metformin in type 2 diabetes in swedenCost effectiveness of dipeptidyl peptidase-4 inhibitors for type 2 diabetes.Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in ArgentinaSaxagliptin and metformin in fixed combination for the treatment of type 2 diabetes in adultsThe Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes MellitusAdding Saxagliptin to Metformin Extended Release (XR) or Uptitration of Metformin XR: Efficacy on Daily Glucose Measures.How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review.When to use discrete event simulation (DES) for the economic evaluation of health technologies? A review and critique of the costs and benefits of DES.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands.Cost-effectiveness of dipeptidyl peptidase-4 inhibitor monotherapy versus sulfonylurea monotherapy for people with type 2 diabetes and chronic kidney disease in Thailand.The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies.The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.Comparison of diabetes-associated secondary healthcare utilization between alternative oral antihyperglycaemic dual therapy combinations with metformin in patients with type 2 diabetes: an observational cohort study.Higher risk of sulfonylurea-associated hypoglycemic symptoms in women with type 2 diabetes mellitus.
P2860

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis.

Item
http://www.wikidata.org/entity/Q45402744
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@en
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@nl
type
label
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@en
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@nl
prefLabel
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@en
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P921
P356
P1433
P1476
Cost effectiveness of saxaglip ...... rdiff diabetes model analysis.
@en
P2093
P2860
P304
P31
P356
10.2165/11597060-000000000-00000
P433
P478
P577
P698
P921